Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT by Kate H. Gartlan, Antiopi Varelias,

Slides:



Advertisements
Similar presentations
Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,
Advertisements

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice by Robert G. Newman,
Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation 
Lung parenchyma-derived IL-6 promotes IL-17A–dependent acute lung injury after allogeneic stem cell transplantation by Antiopi Varelias, Kate H. Gartlan,
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but.
Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.
by Dennis Adeegbe, Robert B. Levy, and Thomas R. Malek
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer
Impaired negative regulation of homeostatically proliferating T cells
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Volume 44, Issue 1, Pages (January 2016)
Novel function for interleukin-7 in dendritic cell development
The tyrosine phosphatase SHP-1 dampens murine Th17 development
Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman,
Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality by Rachelle G. Veenstra, Ryan Flynn, Katharina.
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo by Ying Liu, Ramona.
Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized.
Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies.
IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract by Angela C. Burman, Tatjana Banovic,
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
Tatjana Banovic, Kelli P. A. MacDonald, Kate A. Markey, Edward S
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
by Anil Dangi, Lei Zhang, Xiaomin Zhang, and Xunrong Luo
FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal  Patricia A. Taylor,
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
IL-22 Increases the Innate Immunity of Tissues
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia by Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin.
Volume 18, Issue 5, Pages (May 2003)
Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice by Julie Lang, Bicheng Zhang, Margot Kelly, Jacob.
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease  Haruko Sugiyama,
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
Volume 13, Issue 12, Pages (December 2015)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either.
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
Karima R.R. Siddiqui, Sophie Laffont, Fiona Powrie  Immunity 
Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
IAPs protect host target tissues from graft-versus-host disease in mice by Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Chen Liu, Cynthia Zajac,
IL-6 neutralization decreases T cell proliferation and cytokine production upon restimulation by allogeneic HUVEC. CIITA transduced HUVECs were cocultured.
Bridge to transplant following Bv+Bs regimen.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
IL-17A mediates cutaneous GVHD
Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation by Kate A. Markey, Tatjana.
Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.
Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo by Holger Hackstein, Timucin Taner,
Volume 37, Issue 2, Pages (August 2012)
Endogenous Control of Immunity against Infection: Tenascin-C Regulates TLR4- Mediated Inflammation via MicroRNA-155  Anna M. Piccinini, Kim S. Midwood 
Presentation transcript:

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT by Kate H. Gartlan, Antiopi Varelias, Motoko Koyama, Renee J. Robb, Kate A. Markey, Karshing Chang, Andrew N. Wilkinson, David Smith, Md Ashik Ullah, Rachel D. Kuns, Neil C. Raffelt, Stuart D. Olver, Katie E. Lineburg, Bianca E. Teal, Melody Cheong, Michele W. L. Teng, Mark J. Smyth, Siok-Keen Tey, Kelli P. A. MacDonald, and Geoffrey R. Hill BloodAdv Volume 1(6):341-351 February 14, 2017 © 2017 by The American Society of Hematology

Kate H. Gartlan et al. Blood Adv 2017;1:341-351 © 2017 by The American Society of Hematology

Donor-derived IL-17+ and RORγt+ Th17 cells develop early after allo-SCT in an IL-6-dependent manner. Donor-derived IL-17+and RORγt+Th17 cells develop early after allo-SCT in an IL-6-dependent manner. (A-G) CD4+YFP+ development was assessed in spleen, mesenteric LN (mLN), peripheral LN (pLN) and liver from lethally irradiated allogeneic (B6.IL-17CreRosa26eYFP → B6D2F1) or (B) syngeneic (B6.IL-17CreRosa26eYFP → B6) mice transplanted with G-CSF mobilized grafts. (A) Time course analysis of CD4+YFP+ frequencies and absolute numbers within the CD4+ T-cell compartment d3, d7, d14, and d21 posttransplant (mean ± SEM, n = 4-21 mice per group pooled from 2-4 independent experiments). (B) CD4+YFP+ frequencies and absolute numbers 7 days after syngeneic or allogeneic SCT (mean ± SEM, n = 7-9 mice per group pooled from 2 independent experiments, **P < .01, ***P < .001). (C) CD4+YFP+ frequencies and absolute numbers 7 days after allogeneic SCT in the presence of either IL-6R blocking mAbs or control IgG (mean ± SEM, n = 10 mice per group pooled from 2 independent experiments, ***P < .001). (D) IL-17A expression in naive and donor CD4+ T cells d7 and d21 after transplant in (D-E) spleen and (E) liver (mean ± SEM, n = 10-15 mice per group pooled from 2-3 independent experiments, **P < .01, ***P < .001). (F) YFP+ and YFP– CD4+ T cells isolated from spleen, LNs, and liver by FACS on d7 and d21 followed by qPCR (mean ± SEM, n = 3-4 independent experiments each composed of 10 pooled mice per group, *P < .05). (G) RORγt and Tbet expression by CD4+ T-cell populations isolated from spleen, mLNs, and liver d7 posttransplant. Kate H. Gartlan et al. Blood Adv 2017;1:341-351 © 2017 by The American Society of Hematology

Donor-derived Th17 are highly proinflammatory and plastic in their cytokine profile. Donor-derived Th17 are highly proinflammatory and plastic in their cytokine profile. (A-C) CD4+YFP+ development was assessed in lethally irradiated allogeneic mice transplanted with G-CSF mobilized grafts (B6.IL-17CreRosa26eYFP → B6D2F1). (A) Representative FACS analysis showing IL-17A, IFNγ, IL-22, IL-13, TNF, GM-CSF, and IL-10 cytokine expression posttransplant by splenic CD4+YFP− or CD4+YFP+ populations after short-term in vitro restimulation (d7). (B) Frequencies of cytokine-expressing CD4+ T cells isolated from spleen and assessed at d7 or d21 post-SCT (mean ± SEM, n = ≥5 mice per group, *P < .05, **P < .01, ***P < .001). (C) GM-CSF and TNF coexpression by IL-17A+IFNγ– and IL-17A+IFNγ+ CD4+ T cells at d7 after allo-SCT (n = 6 mice from 1 representative experiment, *P < .0001). DN, double negative (TNF−GM-CSF−). Kate H. Gartlan et al. Blood Adv 2017;1:341-351 © 2017 by The American Society of Hematology

Proinflammatory donor Th17 are induced by alloantigen, IL-12/23, and IFNγ. Proinflammatory donor Th17 are induced by alloantigen, IL-12/23, and IFNγ. (A-F) Donor CD4+ T-cell cytokine expression was examined after (A) syngeneic SCT (WT.B6 → WT.B6) or (A-F) allo-SCT, (A-B,E-F) WT.B6 → B6D2F1 (G-CSF mobilized grafts) or (C-D) WT.B6 or IL-12p40–/– BM, WT.B6 T-cells and B6.TEa T-cells → Balb/c. (A) Proportion of CD4+IL-17A+ T cells coexpressing IFNγ d7 after either allo-SCT or syngeneic transplant (mean ± SEM, n = ≥6 mice per group, **P < .01). (B) Proportion of CD4+IL-17A+ T cells coexpressing IFNγ d7 after allo-SCT in the presence or absence of IL-12p40 blocking antibody treatment (mean ± SEM, n = ≥9 mice per group from 2 independent experiments, **P < .01). (C) Representative FACS analysis of donor TEa transgenic T cells harvested on d3, d5, and d7 after adoptive transfer. (D) Proportion of splenic and mLN CD4+IL-17A+ TEa cells coexpressing IFNγ d5 and d7 after allo-SCT in the presence and absence of donor BM-derived IL-12p40 (mean ± SD, n = 3 mice per group per time point, *P < .05, ***P < .001). (E) Representative FACS analysis and (F) proportion of CD4+IL-17A+ T cells coexpressing IFNγ d7 after allo-SCT in the presence or absence of IFNγ blocking antibody treatment (mean ± SEM, n = 6 mice per group pooled from 2 independent experiments, **P < .01). Kate H. Gartlan et al. Blood Adv 2017;1:341-351 © 2017 by The American Society of Hematology

Donor Th17 plasticity and proinflammatory profile is limited by immunosuppression. Donor Th17 plasticity and proinflammatory profile is limited by immunosuppression. (A-D,F-H) Donor CD4+ T-cell cytokine expression was examined after allo-SCT (A-B,E-F) WT.B6 → B6D2F1 (G-CSF mobilized grafts) or (C-D) WT.B6 or IL-12p40−/− BM, WT.B6 T-cells → Balb/c. (A) Representative FACS analysis of splenic CD4+ T cells and (B) proportion of CD4+IL-17A+ T cells coexpressing IFNγ d7 after allo-SCT in the presence or absence of increasing doses of CsA (mean ± SEM, n = 8 mice per group, pooled from 2 independent experiments, ***P < .001). (C) Representative images and (D) quantitative analysis of IL-12p40-YFP+ cells in mLN explants at d12 posttransplant, unstained tissues were captured by multiphoton confocal microscopy (20× objective) with spectral detection and linear unmixing (unmixed channels are shown: blue = CFP; yellow = YFP; scale bars = 300 μm). (E) Cytokine production by BMDCs was assessed in response to overnight stimulation in the presence and absence of CsA. Data are expressed as fold change relative to CpG-only stimulation (mean ± SEM, data pooled from 2 independent experiments, ***P < .001). (F) Representative FACS analysis of splenic CD4+ T cells, (G) proportion of CD4+IL-17A+ T cells coexpressing IFNγ, (H) frequency of cytokine-positive CD4+ T cells d7 after allo-SCT in the presence or absence of CsA (50 mg/kg) or Rapa (rapamycin) (0.6 μg/kg) (mean ± SEM, n = 6 mice per group, *P < .05, **P < .01, ***P < .001). Kate H. Gartlan et al. Blood Adv 2017;1:341-351 © 2017 by The American Society of Hematology

Proinflammatory Th17 in patients following allo-SCT. Proinflammatory Th17 in patients following allo-SCT. (A) Representative FACS analysis and (B) proportion of peripheral blood CD4+IL-17A+ T cells expressing IFNγ in healthy donors and d14, d120, and d240 after clinical allo-SCT and CsA treatment (∼d0-d100) (mean ± SEM, d14, n = 11 patients, d240, n = 12 patients). (C) Total IL-17A+IFNγ+ concentrations in human peripheral blood d14 and d240 after clinical allo-SCT and CsA treatment (mean ± SEM, d14, n = 10 patients, d240, n = 10 patients, ***P < .001). (D) Proportion of human peripheral blood IL-17A+IFNγ+ and IL-17A+IFNγ– CD4+ T cells coexpressing TNF on d14, d120, and d240 posttransplant (paired analyses, d14, n = 6 patients, d120, n = 3 patients, and d240, n = 12 patients, *P < .05, **P < . 01, ***P < .001). (E) Pearson correlation analysis of systemic IL-17A and IFNγ concentrations in healthy donor plasma. (F) Cross-correlation analysis of systemic IL-17A, IFNγ, and TNF concentrations in patient plasma over time derived from allo-SCT recipients on days −7, 0, 7, 14, 30, 60, 90, 120, 180, 240, and 360 (n = 53 patients, ***P < .001). n.s., not significant; TNF+ve, tumor necrosis factor positive. Kate H. Gartlan et al. Blood Adv 2017;1:341-351 © 2017 by The American Society of Hematology